Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUENASDAQ:IPANASDAQ:MDNANASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$0.66+13.0%$0.71$0.45▼$1.99$49.39M1.41421,276 shs458,578 shsIPAImmunoPrecise Antibodies$1.01+6.7%$0.55$0.27▼$1.07$46.22M0.122.48 million shs1.78 million shsMDNAMedicenna Therapeutics$0.29$0.15▼$0.84$10.93M1.3160,047 shs1.27 million shsMURAMural Oncology$2.47+1.2%$2.55$0.95▼$4.74$42.65M3.361.30 million shs114,212 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma0.00%+3.11%-2.11%-33.42%-51.44%IPAImmunoPrecise Antibodies0.00%+38.38%+106.08%+138.66%-1.86%MDNAMedicenna Therapeutics0.00%0.00%0.00%0.00%0.00%MURAMural Oncology0.00%-2.37%-17.11%-35.84%-23.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCUECue Biopharma3.9946 of 5 stars3.54.00.04.70.60.80.6IPAImmunoPrecise Antibodies2.059 of 5 stars3.53.00.00.02.00.00.6MDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AMURAMural Oncology2.7408 of 5 stars3.35.00.00.00.01.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 3.00Buy$3.00357.67% UpsideIPAImmunoPrecise Antibodies 3.00Buy$4.00296.04% UpsideMDNAMedicenna Therapeutics 3.00Buy$2.50∞ UpsideMURAMural Oncology 2.60Moderate Buy$13.00426.32% UpsideCurrent Analyst Ratings BreakdownLatest MDNA, CUE, IPA, and MURA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.00 ➝ $5.004/1/2025IPAImmunoPrecise AntibodiesBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSpeculative Buy ➝ Speculative Buy$3.00 ➝ $3.003/31/2025IPAImmunoPrecise AntibodiesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$7.00 ➝ $5.003/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold(Data available from 6/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$9.29M5.32N/AN/A$0.28 per share2.34IPAImmunoPrecise Antibodies$18.16M2.55N/AN/A$0.93 per share1.09MDNAMedicenna TherapeuticsN/AN/AN/AN/A$0.32 per shareN/AMURAMural OncologyN/AN/AN/AN/A$8.22 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$40.67M-$0.670.00N/AN/A-507.87%-228.43%-114.66%8/13/2025 (Estimated)IPAImmunoPrecise Antibodies-$20.13M-$1.160.00N/AN/A-190.76%-88.87%-49.26%7/3/2025 (Estimated)MDNAMedicenna Therapeutics-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/AMURAMural Oncology-$128.51M-$7.67N/AN/AN/AN/A-83.39%-70.70%8/12/2025 (Estimated)Latest MDNA, CUE, IPA, and MURA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025MURAMural Oncology-$2.12-$1.93+$0.19-$1.93N/AN/A5/12/2025Q1 2025CUECue Biopharma-$0.14-$0.17-$0.03-$0.17$0.90 million$0.42 million3/28/2025Q4 2024CUECue Biopharma-$0.14-$0.13+$0.01-$0.13$1.70 million$1.80 million3/28/2025Q3 2025IPAImmunoPrecise Antibodies-$0.06-$0.06N/A-$0.46$6.59 million$4.23 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/AIPAImmunoPrecise AntibodiesN/AN/AN/AN/AN/AMDNAMedicenna TherapeuticsN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A1.031.03IPAImmunoPrecise Antibodies0.452.322.11MDNAMedicenna TherapeuticsN/A9.579.57MURAMural OncologyN/A5.085.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%IPAImmunoPrecise Antibodies6.70%MDNAMedicenna Therapeutics12.38%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma10.78%IPAImmunoPrecise Antibodies6.83%MDNAMedicenna Therapeutics33.10%MURAMural Oncology2.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma6075.35 million67.23 millionOptionableIPAImmunoPrecise Antibodies8045.76 million42.64 millionNot OptionableMDNAMedicenna Therapeutics1669.64 million46.59 millionNot OptionableMURAMural Oncology11917.27 million16.89 millionOptionableMDNA, CUE, IPA, and MURA HeadlinesRecent News About These CompaniesForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 16, 2025 | markets.businessinsider.comBlackRock discloses 1.64% stake in Mural OncologyJune 13, 2025 | investing.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcJune 13, 2025 | markets.businessinsider.comBlackRock discloses 1.39% stake in Mural OncologyJune 12, 2025 | investing.comBlackRock Reveals 1.58% Holding in Mural OncologyJune 5, 2025 | msn.comCincinnati hospital honors late doctor with mural tributeMay 24, 2025 | local12.comGoldman Sachs adjusts positions in Mural OncologyMay 21, 2025 | investing.comMural Oncology Announces Number of Relevant Securities in IssueMay 19, 2025 | globenewswire.comBlackRock discloses stake in Mural Oncology plcMay 15, 2025 | investing.comLongtime Lawrence artist Louis Copt, known for Kansas landscape paintings, diesMay 10, 2025 | www2.ljworld.comBlackRock discloses stake in Mural OncologyMay 3, 2025 | investing.comGoldman Sachs discloses stake in Mural OncologyMay 3, 2025 | investing.comMural Oncology plc Opening Position Disclosure Under Irish Takeover RulesApril 30, 2025 | quiverquant.comFORM 8.1(a) & (b) - Mural Oncology plcApril 30, 2025 | globenewswire.com‘Final mark on his legacy’: Wood County artists dedicate work to muralist who died in JanuaryApril 30, 2025 | msn.comLuka Dončić donates entire cost of restoring vandalized Kobe Bryant mural in downtown Los AngelesApril 29, 2025 | msn.com“There is a life afterwards”: New downtown Dallas mural honors cancer survivorsApril 29, 2025 | keranews.orgParkwood Master Fund Ltd - Form 8.3 - Mural Oncology PlcApril 24, 2025 | uk.finance.yahoo.comForm 8.3 - Mural Oncology plcApril 22, 2025 | finance.yahoo.comBoston-area cancer research lab to cease drug trials, lay off 117April 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBroadcom Earnings Preview: AVGO Stock Near Record HighsBy Leo Miller | June 3, 2025View Broadcom Earnings Preview: AVGO Stock Near Record HighsMDNA, CUE, IPA, and MURA Company DescriptionsCue Biopharma NASDAQ:CUE$0.66 +0.08 (+13.00%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$0.69 +0.03 (+5.11%) As of 06/18/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.ImmunoPrecise Antibodies NASDAQ:IPA$1.01 +0.06 (+6.73%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$1.00 -0.01 (-0.50%) As of 06/18/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign. In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.Medicenna Therapeutics NASDAQ:MDNAMedicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.Mural Oncology NASDAQ:MURA$2.47 +0.03 (+1.23%) Closing price 06/18/2025 04:00 PM EasternExtended Trading$2.46 -0.01 (-0.36%) As of 06/18/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
